132 related articles for article (PubMed ID: 12556245)
1. Hypersensitivity vasculitis induced by cefoperazone/sulbactam.
Islek I; Baris S; Katranci AO; Ariturk E; Gurses N
Ann Clin Microbiol Antimicrob; 2003 Jan; 2():1. PubMed ID: 12556245
[TBL] [Abstract][Full Text] [Related]
2. Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam.
Zhou L; Bao J; Ma J
Front Pharmacol; 2019; 10():1342. PubMed ID: 31798450
[No Abstract] [Full Text] [Related]
3. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review.
Wang Z; Li Z; Luo S; Yang Z; Xing Y; Pu C; Dong J
J Int Med Res; 2021 Jun; 49(6):3000605211025367. PubMed ID: 34162261
[TBL] [Abstract][Full Text] [Related]
4. A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis.
Tsujikawa K; Kuwayama K; Miyaguchi H; Kanamori T; Iwata Y; Inoue H; Kishi T
J Forensic Sci; 2008 Jan; 53(1):226-31. PubMed ID: 18279263
[TBL] [Abstract][Full Text] [Related]
5. Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger LH; Piscitelli SC; Occhipinti DJ; Resnick DJ; Rodvold KA
Ann Pharmacother; 1994 Jun; 28(6):703-7. PubMed ID: 7919553
[TBL] [Abstract][Full Text] [Related]
6. Cefoperazone/sulbactam-induced hemolytic anemia.
Sun XM; Liu LH; Wu Q; Wang HG
J Postgrad Med; 2023; 69(1):46-49. PubMed ID: 34528516
[TBL] [Abstract][Full Text] [Related]
7. In-vitro susceptibility of Burkholderia pseudomallei to cefoperazone-sulbactam combination.
Koay AS; Rohani MY; Cheong YM
Med J Malaysia; 1997 Jun; 52(2):158-60. PubMed ID: 10968074
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics and toleration of intravenously administered cefoperazone and sulbactam when given as single agents or in combination.
Reitberg DP; Whall TJ; Chung M; Blickens D; Swarz H; Arnold J
Antimicrob Agents Chemother; 1988 Jan; 32(1):42-6. PubMed ID: 3348612
[TBL] [Abstract][Full Text] [Related]
10. A case report of rash induced by cefoperazone sodium and sulbactam sodium plus metronidazole sodium chloride combined with morphine hydrochloride.
Huang J; Zhu X; Jiang C; Liu Z
Ann Palliat Med; 2020 Nov; 9(6):4377-4383. PubMed ID: 33302688
[TBL] [Abstract][Full Text] [Related]
11. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
12. Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms.
Rice LB; Carias LL; Etter L; Shlaes DM
Antimicrob Agents Chemother; 1993 May; 37(5):1061-4. PubMed ID: 8390809
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Drug-Induced Immune Haemolytic Anaemia Caused by Cefoperazone-Tazobactam/ Sulbactam Combination Therapy.
Wu Y; Wu Y; Ji Y; Liang J; He Z; Liu Y; Tang L; Guo G
Front Med (Lausanne); 2021; 8():697192. PubMed ID: 34485334
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
15. Acute localized exanthematous pustulosis caused by cefoperazone and sodium sulbactam.
Qu YJ; Jin SB; Han XC; Zheng LQ
An Bras Dermatol; 2016; 91(6):808-810. PubMed ID: 28099605
[TBL] [Abstract][Full Text] [Related]
16. Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Schwartz JI; Jauregui LE; Bachmann KA; Martin ME; Reitberg DP
Antimicrob Agents Chemother; 1988 May; 32(5):730-5. PubMed ID: 3395103
[TBL] [Abstract][Full Text] [Related]
17. Risk-factor analysis and predictive-model development of acute kidney injury in inpatients administered cefoperazone-sulbactam sodium and mezlocillin-sulbactam sodium: a single-center retrospective study.
Zhang R; Gao L; Chen P; Liu W; Huang X; Li X
Front Pharmacol; 2023; 14():1170987. PubMed ID: 37361226
[No Abstract] [Full Text] [Related]
18. Risk Factors for Cefoperazone/Sulbactam-Induced Coagulation Disorder.
Miao W; Guo J; Cheng H; Zhao Q
Infect Drug Resist; 2023; 16():6277-6284. PubMed ID: 37766881
[TBL] [Abstract][Full Text] [Related]
19. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
He X; Huang W; Wan X; Li X; Chang Q; Ding L
J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
